CancerWorld

The alpha-synuclein, a protein long associated with Parkinson’s disease may hold the key to melanoma proliferation. The study, published in Science Advances, on 9 April, suggests that while excess alpha-synuclein results in cell death in neurons, conversely, it enables uncontrolled…

It was 2018, and I was a fifth-year medical student at Yerevan State Medical University. Word spread that our new oncology professor was someone extraordinary: Gevorg Tamamyan - a Harvard-trained, Nature-published pioneer of pediatric oncology in Armenia and president of…

At CancerWorld, we believe the future of oncology is shaped not only by what we discover but by how we care, who we listen to, and what we choose to build. On our dual cover, we feature Suheir Rasul. As…

For decades, the fight against cancer has been waged through tireless human intellect, groundbreaking scientific discovery, and the unwavering compassion of clinicians. We have mapped genomes, developed targeted therapies, and celebrated incremental victories that have collectively extended and improved countless…

China’s oncologists want to see robust evidence before putting their faith in traditional remedies. Practitioners of traditional Chinese medicine struggle with concepts of experimental medicine and animal models. But interest is growing in finding ways to bridge that gap in…

A new, innovative pipeline fusing genomics, proteomics and modelling in animals and chicken eggs is pinpointing new treatments for children with rare and relapsed cancers in Canada. Researchers in Canada have used fertilized chicken eggs to grow tumors from children…

The gut microbiota can transform cholesterol-derived bile acids into metabolites capable of blocking androgen receptors and strengthening anti-cancer immunity. The study, published in Cell, April 15, demonstrates how one of the microbiota-derived secondary bile acids is capable of suppressing tumour…

“I mean, while I was reading the book you gave me about Umberto Veronesi,” I said, “there’s this expression: As you set out for Ithaca, hope your road is a long one, full of adventure, full of discovery. You wrote…

What does it take to change the odds in cancer care? Innovation? Yes. But also: persistence. Collaboration. The refusal to accept that some lives matter less because of where they’re born. In this issue of CancerWorld, we focus not just…

I grew up around a lot of physicians,” begins Adrian Gottschalk, President and CEO of Foghorn Therapeutics, a biotech company redefining how we understand and treat complex diseases by targeting the chromatin regulatory system. “My late father was a professor…